Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
NEWSLETTER  |  PRINT VERSION
Facebook
Twitter
LinkedIn
Cancer World Magazine
Cancer World Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine > News > A step forward in prostate cancer screening optimisation
  • News

A step forward in prostate cancer screening optimisation

  • 26 February 2020
  • Elena Riboldi
A step forward in prostate cancer screening optimisation
Total
0
Shares
0
0
0
0
0
A single prostate-specific antigen (PSA) measurement in midlife may help to personalise prostate cancer screening, resulting in a reduced risk of overdiagnosis and overtreatment of indolent cancers. The authors of the study just published in JAMA Network Open came to this conclusion after finding that in a cohort of nearly 11,000 man aged 55 to 60 years, baseline PSA level correlated with long-term risk of clinically significant prostate cancer. This study is likely to re-open the debate about the utility of PSA measurement as a screening tool. Introduced in the 1990s, it enjoyed wide acceptance until recent years, when its significance has been called into question. “Until a more accurate biomarker is identified, PSA remains the best screening tool available for early prostate cancer diagnosis” stated Evan Kovac, urologist at Montefiore Medical Center (Bronx, New York) and first author of the article. “Therefore, it is imperative to improve the detection of clinically significant prostate cancer while minimizing overdiagnosis and overtreatment through a more nuanced approach to PSA screening.” The study consisted in a secondary analysis of a cohort of 10,968 men aged 55 to 60 years enrolled in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. The risk of being diagnosed with a clinically significant prostate cancer during 13 years of follow-up was lower among men with a baseline PSA level less than 0.49 ng/mL and higher among men with a baseline level more than 2.00 ng/mL. Of note, 83% of participants had baseline PSA levels less than 2.00 ng/mL. “At a time when the concern regarding the overdiagnosis and overtreatment of indolent prostate cancer has led to intense scrutiny of the value of PSA levels as an effective screening tool, our data on the increasing risks associated with higher baseline PSA levels can be used to determine the optimal prostate cancer screening strategy for individual patients – Kovac explained – The low 13-year actuarial risk of a clinically significant prostate cancer diagnosis in middle-aged men with a baseline PSA level less than 2.00 ng/mL suggests that men younger than 60 years with PSA levels of 1.00 to 1.99 ng/mL can undergo less intensive screening than men with higher baseline PSA levels. Men with baseline PSA levels less than 1.00 ng/mL may wish to discontinue screening.” Data from this study may be used to inform patients for shared decision-making.
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • PSA
  • screening
Avatar
Elena Riboldi

Previous Article
  • Profiles

Chiara Gasparotto – winning the case for better access to radiotherapy

  • 11 February 2020
  • Peter McIntyre
View Post
Next Article
  • News

More evidence-based info on off-patent oncology drugs

  • 2 March 2020
  • Editorial Staff
View Post
You May Also Like
View Post
  • News

Study brings mass biparametric MRI screening for prostate cancer a step closer

  • Janet Fricker
  • 23 February 2021
View Post
  • News

Oncology providers urged to offer healthy life style advice to breast cancer survivors

  • Janet Fricker
  • 19 February 2021
View Post
  • News

Studies provide clarity on breast cancer genes for genetic panels

  • Janet Fricker
  • 9 February 2021
View Post
  • News

EC publishes route map for tackling cancer

  • Janet Fricker
  • 5 February 2021
View Post
  • News

Therapy targeting androgen receptors opens new chapter for hormone driven breast cancers

  • Janet Fricker
  • 27 January 2021
View Post
  • News

Coffee may protect against prostate cancer

  • Janet Fricker
  • 20 January 2021
View Post
  • News

Financial burden on older adults with advanced cancer worsens quality of life

  • Janet Fricker
  • 15 January 2021
View Post
  • News

Integrated imaging opens the way for virtual biopsies

  • Janet Fricker
  • 15 January 2021

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancer World archive
Latest news
  • Study brings mass biparametric MRI screening for prostate cancer a step closer
    • 23 February 2021
  • Oncology providers urged to offer healthy life style advice to breast cancer survivors
    • 19 February 2021
  • Studies provide clarity on breast cancer genes for genetic panels
    • 9 February 2021
  • EC publishes route map for tackling cancer
    • 5 February 2021
  • Therapy targeting androgen receptors opens new chapter for hormone driven breast cancers
    • 27 January 2021
Latest printed issue
Article
  • Immunotherapy toxicities demand a joined up approach from oncologists and organ specialists
    • 24 February 2021
  • Beating cancer is complex – our messaging must be clear
    • 11 February 2021
  • Who wouldn’t want to cure 100% of childhood cancers?
    • 29 January 2021
Newsletter

Don't miss our newsletter

Would you like to receive our bimonthly e-newsletter with the latest news from Cancer World magazine?

Subscribe now
Social

Would you follow us ?

Contents
  • Moving towards efficiency in cancer care: Examples
    • 8 February 2021
  • World Cancer Day: we commemorate Professor Agim Sallaku
    • 3 February 2021
  • Gordon McVie 1945–2021: a lifetime dedicated to defeating cancer
    • 22 January 2021
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancer World is managed by SPCC Sharing Progress in Cancer Care | Piazza Indipendenza 2, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.